
CMRX
Healthcare · Biotechnology · $801.1M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2025
EPS trend, 90 days to now · +6.9% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 26, 2025 | Before the open | -0.28 | -0.25 | +9.1% |
| Nov 7, 2024 | Before the open | -0.24 | -0.26 | -8.3% |
| Aug 13, 2024 | Before the open | -0.23 | -0.23 | 0.0% |
| May 1, 2024 | Before the open | -0.22 | -0.25 | -13.6% |
| Feb 29, 2024 | Before the open | -0.24 | -0.20 | +16.7% |
| Nov 2, 2023 | Before the open | -0.23 | -0.27 | -17.4% |
| Aug 3, 2023 | Before the open | -0.24 | -0.21 | +12.5% |
| May 4, 2023 | Before the open | -0.25 | -0.24 | +4.0% |
| Mar 2, 2023 | Before the open | -0.24 | -0.24 | 0.0% |
| Nov 3, 2022 | Before the open | 2.14 | 2.75 | +28.5% |
| Aug 8, 2022 | After the close | -0.24 | -0.27 | -12.5% |
| May 16, 2022 | Before the open | -0.33 | -0.28 | +15.2% |
| Mar 1, 2022 | Before the open | -0.17 | -0.45 |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation…
| -164.7% |
| Nov 4, 2021 | Before the open | -0.15 | -0.21 | -40.0% |
| Aug 5, 2021 | Before the open | -0.19 | -0.21 | -10.5% |
| May 6, 2021 | Before the open | -0.41 | -1.21 | -195.1% |
| Feb 25, 2021 | Before the open | -0.20 | -0.19 | +5.0% |
| Nov 5, 2020 | Before the open | -0.17 | -0.18 | -5.9% |
| Aug 10, 2020 | Before the open | -0.17 | -0.16 | +5.9% |
| May 7, 2020 | Before the open | -0.15 | -0.17 | -13.3% |
| Feb 25, 2020 | Before the open | -0.17 | -0.06 | +64.7% |
| Nov 5, 2019 | Before the open | -0.22 | -0.15 | +31.8% |
| Aug 8, 2019 | Before the open | -0.37 | -0.35 | +5.4% |
| May 9, 2019 | Before the open | -0.35 | -0.35 | 0.0% |
| Mar 5, 2019 | Before the open | -0.35 | -0.29 | +17.1% |
| Nov 8, 2018 | Before the open | -0.42 | -0.33 | +21.4% |
| Aug 8, 2018 | Before the open | -0.44 | -0.39 | +11.4% |
| May 7, 2018 | Before the open | -0.43 | -0.42 | +2.3% |
| Mar 1, 2018 | Before the open | -0.47 | -0.38 | +19.1% |